Methandienone Injection 100mg/ml 10ml Vial by Genesis

Usage

1. Verify vial integrity and confirm solution is clear to pale yellow with no particulate matter before drawing — cloudiness indicates potential contamination and the vial should be discarded, as compromised sterility negates AR-binding potency.
2. Allow the vial to reach 20–22 °C (room temperature) prior to drawing; the oil carrier flows more evenly at this temperature, ensuring that the volume drawn accurately reflects the intended receptor-binding dose.
3. Disinfect the vial stopper with a 70 % isopropyl alcohol swab and allow it to dry for 30 seconds before insertion of the draw needle.
4. Draw the calculated volume using a fresh needle — switching to a second sterile needle for injection prevents oil-film contamination and reduces injection-site reaction risk linked to blunted tip penetration.
5. Administer via deep intramuscular injection (gluteus, vastus lateralis, or deltoid) using Z-track technique to minimise oil migration into subcutaneous tissue, which can impair absorption kinetics and delay AR-occupancy onset.
6. Rotate injection sites systematically across the cycle and store the opened vial at 2–8 °C; discard after 28 days of first puncture regardless of remaining volume to maintain the sterility standard validated by Genesis's LAL endotoxin testing.

Warnings

Frequently asked questions

How does methandienone bind to the androgen receptor compared to testosterone and DHT?

Methandienone binds the intracellular androgen receptor (AR) with a relative binding affinity (RBA) of approximately 56–73 % of DHT (DHT = 100 %), placing it substantially above testosterone (RBA ≈ 44 %) on standardised nuclear AR binding assays. This affinity profile means the compound directly activates AR-driven transcription of genes governing nitrogen retention and muscle protein synthesis, producing anabolic signalling in its parent form rather than requiring 5α-reduction.

Why does methandienone's C-1/C-2 double bond make it a poor substrate for 5α-reductase?

The Δ1 double bond introduced between carbon-1 and carbon-2 of the methandienone backbone sterically and electronically disfavours the enzymatic reduction step that 5α-reductase performs on testosterone to generate DHT. As a result, methandienone is not efficiently converted to a more potent androgen peripherally; instead, AR occupancy occurs predominantly via the parent compound, reducing scalp, skin, and prostate-specific androgenic metabolite burden compared to testosterone at equivalent anabolic doses.

What role does 17α-methylation play in the receptor-binding stability of injectable methandienone at 100mg/ml?

17α-methylation blocks hepatic C-17 oxidation, the metabolic pathway that rapidly deactivates non-methylated androgens. In the injectable oil matrix, this same modification contributes to molecular stability at high concentration: the active molecule resists degradation in the carrier, allowing Genesis to formulate a 100 mg/ml solution that retains full receptor-binding potency through shelf life — confirmed by HPLC assay on finished vials against a certified methandienone reference standard.

How should I draw and measure doses from a 100mg/ml methandienone vial using an insulin syringe?

A standard 1 ml insulin syringe graduated in 0.01 ml increments allows doses as precise as 10 mg (0.1 ml) to be measured from a 100 mg/ml vial. Clean the rubber stopper with an alcohol swab, draw the required volume slowly to avoid air bubbles, and switch to a fresh injection needle before administering. Because 100 mg/ml is a dense oil solution, allow the syringe to reach room temperature — approximately 20–22 °C — before drawing to reduce viscosity and ensure accurate volume measurement.

What are the correct storage conditions for a Genesis Methandienone Injection 10ml vial after first opening?

After first puncture, store the opened vial at 2–8 °C (standard pharmaceutical refrigerator range) away from direct light, and use within 28 days — the industry-standard multi-dose vial in-use period for oil-based injectables. Do not freeze, as crystallisation at sub-zero temperatures can alter oil homogeneity. Inspect the solution visually before each draw: it should remain clear to slightly yellow; discard if particulate matter, cloudiness, or colour change is observed, as these may indicate contamination or degradation. (2) angle_used

Manufacturer

Genesis positions its injectable methandienone line within a product portfolio that spans oral androgens, peptide-class compounds, ancillaries, and — critically — oil-based injectable steroids, each requiring a distinct analytical and sterility framework that differs from its tablet manufacturing operations. For the Methandienone Injection 100 mg/ml product specifically, the quality architecture addresses two challenges that are absent from the oral side of the portfolio: concentration accuracy in a non-aqueous oil matrix and the microbiological safety standard demanded of any parenteral preparation. Concentration is anchored by HPLC quantification of the finished injectable solution against a certified methandienone primary reference standard — a step that must account for oil-matrix interference in a way tablet assays do not require. Microbiological safety is addressed through LAL (Limulus Amebocyte Lysate) endotoxin testing conducted on finished vials, providing a quantitative endotoxin burden figure rather than a qualitative pass/fail approximation. Both analytical outputs are generated under GMP-documented conditions, with records that accompany each batch through release. This injectable-specific quality structure reflects Genesis's recognition that its injectable portfolio occupies a pharmacologically and analytically distinct category within its broader product line — one where potency confirmation and sterility assurance must be co-validated rather than treated as independent quality attributes.